#2779 THROMBOMODULIN IS A SPECIFIC MARKER OF ENDOTHELIAL DYSFUNCTION IN HEMODIALYSIS PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE

Abstract Background and Aims Non-alcoholic fatty liver disease (NAFLD) is associated with endothelial dysfunction which a common problem in hemodialysis patients risk for high cardiovascular mortality hemodialysis. Thrombomodulin promising marker of cell injury different pathological conditions. This study evaluates the additive effect non-alcoholic prevalent HD on dysfunction. Methods A case-control was conducted 60 end-stage renal (ESRD) conventional hemodialysis: group A: 30 NAFLD, B: without control apparently healthy subjects. Excluding elderly, diabetic patients, chronic Liver disease, advanced heart Failure, active infection, COVID-19 autoimmune diseases catheters. measured all participants by ELISA technique. Results could detect NAFLD at Cut off value <0.8 ng/ml sensitivity 53.33%, specificity 80%, PPV 72.7%, NPV 63.2%. On comparing (4.378±3.762 ng/ml), Non-NAFLD (1.126±0.591 (0.755±0.314 ng/ml) there significant difference (P-value<0.001). Post hoc analysis showed significantly levels {NAFLD versus Non-NAFLD} control} p-value<0.001, 0.001 respectively while no between p-value 0.792. positive thrombomodulin have 2.5 times having There correlation variables study. Conclusions can be used as specific Non Alcoholic disease.